Try our Advanced Search for more refined results
Life Sciences
-
March 06, 2026
Fed. Circ. Won't Reinstate $2M Sepsis-Testing Patent Verdict
The Federal Circuit on Friday refused to revive the $2 million jury verdict Magnolia Medical Technologies Inc. won in its sepsis-testing patent infringement suit against Kurin Inc., affirming a Delaware federal judge's decision to throw out the verdict after trial.
-
March 06, 2026
NJ Talc Suit Will Proceed Amid Beasley Allen DQ Appeal
The New Jersey Supreme Court has declined to stay multicounty litigation over Johnson & Johnson's talc-based baby powder brought by hundreds of women who allege their ovarian cancer was linked to the product, while Beasley Allen appeals its removal as plaintiff's counsel over a firm partner's collaboration with the pharmaceutical giant's former outside counsel.
-
March 06, 2026
Sanofi Selling Medley Unit To Brazilian Drug Co. For $500M
French drugmaker Sanofi will sell 100% of Medley, one of Brazil's leading generic drug brands, to Brazilian pharmaceutical conglomerate Grupo EMS, the companies announced Friday.
-
March 06, 2026
Express Scripts Ducks RICO Suit Over Acthar Price Hike
Express Scripts Inc. and its affiliates may have worked with drugmaker Mallinckrodt to hike the price of seizure medication Acthar from $40 to $40,000, but a proposed class action by third-party payors failed to allege the high prices were a result of fraud, a Pennsylvania federal judge ruled.
-
March 06, 2026
Pa. High Court Snapshot: AG Powers, Gun Parts, CEO Bonus
The Pennsylvania Supreme Court this month will revisit a ruling on the state attorney general's power over civil suits brought by county-level district attorneys in a case stemming from the Philadelphia and Pittsburgh district attorneys' objections to a $26 billion opioid settlement.
-
March 06, 2026
Baker McKenzie Guides Servier On $2.5B Oncology Deal
French pharmaceutical group Servier said Friday that it has agreed to acquire Day One for about $2.5 billion in cash, with legal guidance from Baker McKenzie.
-
March 05, 2026
Telehealth Co. Swaps In Gordon Rees In Novo's GLP-1 Fight
A telehealth platform facing allegations from Novo Nordisk that it falsely advertised Ozempic alternatives has picked new counsel in the dispute, withdrawing attorneys from Foley & Lardner LLP and Miller Nash LLP and substituting in two lawyers from Gordon Rees Scully Mansukhani LLP.
-
March 05, 2026
Fintech Sues Deutsche Bank, Pathward Over Pharma Flags
A self-described barter-based payment platform sued Deutsche Bank AG and Pathward NA, alleging it was improperly placed on an industry blacklist following the banks' assertions it was "transaction laundering" for companies selling gray-market peptides.
-
March 05, 2026
Top Patent Officials To Review Sanofi's Double Patenting Win
U.S. Patent and Trademark Office Director John Squires on Thursday announced he'll be reviewing whether the Patent Trial and Appeal Board properly approved Sanofi's patent application after an obviousness-type double patenting rejection.
-
March 05, 2026
Pharma Co. Investors Secure Class Cert. Over FDA Obstacles
A Pennsylvania federal judge has granted certification to a group of Verrica Pharmaceuticals Inc. investors who claim the company defrauded them by hiding obstacles it faced in obtaining approval from the U.S. Food and Drug Administration for its lead product, though she made a slight change to the class definition to avoid what she called a "heads I win, tails you lose strategy."
-
March 05, 2026
Drugmaker Aquestive Hit With Suit Over FDA Approval Delay
Pharmaceutical company Aquestive Therapeutics Inc. has been hit with a proposed class action accusing it of harming investors by failing to disclose the likelihood that the U.S. Food and Drug Administration would delay approval of the company's drug application for its allergic reaction treatment.
-
March 05, 2026
Pfizer Gets OK For $29M SEC Payout From Insider Case
A New York federal judge on Thursday approved a request from the U.S. Securities and Exchange Commission and Pfizer to have $29 million paid out to a Pfizer subsidiary from the roughly $75.2 million distribution left over from a $602 million insider trading deal.
-
March 05, 2026
Progenity Investors' $1M Billing Fraud Suit Deal Gets Final OK
Genetic test distributor Progenity Inc., now known as Biora Therapeutics Inc., has received final approval of a $1 million settlement with investors, resolving claims that it made misleading statements ahead of its June 2020 initial public offering about its practice of overbilling the government.
-
March 05, 2026
Fed. Circ. Mulls Patents In Penile Implant Trade Secret Win
A Federal Circuit panel on Thursday grilled both sides in a trade secret dispute over penile implants that resulted in an $18.3 million judgment against defendants, repeatedly questioning attorneys about whether existing patents doomed the trade secrets claimed by International Medical Devices and its founder, Dr. James Elist.
-
March 05, 2026
9th Circ. Judge 'Frustrated' At DOJ Position On Anti-Trans EOs
A Ninth Circuit judge said Thursday he's "very frustrated" with the Trump administration's argument that a district court judge acted prematurely by partly blocking executive orders to end funding for gender-affirming care, saying it's "pretty clear" the government was poised to do exactly that.
-
March 05, 2026
Squires' Newest Quick Order Grants 5 Petitions, Rejects 4
The latest bulk order from U.S. Patent and Trademark Office Director John Squires on America Invents Act patent challenges instituted five petitions while denying four others on discretionary grounds, including three brought by Samsung.
-
March 05, 2026
Fla. Lab Pays $980K To Settle Kickback Allegations
A laboratory in Florida agreed to pay $980,000 to resolve allegations that it provided kickbacks to marketers for referring Medicare beneficiaries to use its services, according to a Thursday statement from the U.S. Department of Justice.
-
March 05, 2026
Insurer Seeks Win In $6.3M Coverage Row With Pot Tester
James River Insurance Co. is asking a Mississippi federal court to grant it a win in its suit to deny coverage of a $6.3 million default judgment against a cannabis testing company, saying the company breached its policy by not cooperating with the insurer.
-
March 04, 2026
Wheeling & Appealing: The Latest Must-Know Appellate Action
If this month's circuit calendars were a March Madness bracket, we'd struggle to pick the top-seeded showdown. Big Pharma against the False Claims Act, or big business against President Donald Trump's visa fees? A big bank's view of "human life wagers," or en banc review in a State Farm class action?
-
March 04, 2026
CVS Beats Antitrust Suit Over 340B Drug Program, For Good
CVS Health Corp. permanently defeated a proposed antitrust class action alleging it forced hospitals in a discount drug program to use its third-party administrator for savings, when a Pennsylvania federal judge ruled Tuesday that hospitals aren't required to contract with CVS and can pick Walgreens or other participating pharmacies to contract with.
-
March 04, 2026
Del. Judge Mocks IP Owner, But Still: 'Defendants Win? No!'
U.S. District Judge Richard G. Andrews has refused to dismiss New Directions Technology Consulting's patent infringement litigation over pacemakers and glucose monitors against Abbott Laboratories, but he had choice words for both parties when doing so.
-
March 04, 2026
Regeneron, Sanofi Didn't Warn About Cancer Risk, Suit Says
Regeneron Pharmaceuticals and Sanofi-Aventis were sued Tuesday in Georgia federal court by a woman who said she experienced rapid progression of cutaneous T-cell lymphoma after getting injections of dupilumab, a medication the companies sell as Dupixent as a treatment for inflammation.
-
March 04, 2026
Zantac Investor Class Action Time-Barred, Pa. Judge Rules
The maker of heartburn and acid reflux relief tablet Zantac has defeated a securities fraud class action claiming the company hid for decades the cancer risks associated with the drug, causing a stock price drop when the truth was revealed, after a Pennsylvania federal judge ruled Wednesday that the claims were untimely.
-
March 04, 2026
GAO Denies Protest Of $39.5M Defense Logistics Contract
The Defense Logistics Agency reasonably concluded that a pharmaceutical company was at fault for any missubmitted bids, the U.S. Government Accountability Office said, denying the company's protest of a $39.5 million contract for potassium chloride tablets.
-
March 04, 2026
9th Circ. Hesitant To Revive Implant Suit Against Medtronic
A Ninth Circuit panel cast doubt Wednesday on a Washington man's attempt to revive a negligence lawsuit against Medtronic for allegedly not assisting him when his spinal implant malfunctioned, hinting that his failure to find an expert witness to testify the device caused his pain may be fatal to the case.
Expert Analysis
-
4 Developments That Defined The 2025 Ethics Landscape
The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.
-
Navigating AI In The Legal Industry
As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.
-
How Fractional GCs Can Manage Risks Of Engagement
As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.
-
2025 Legal Milestones That Will Shape Psychedelics Sector
As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.
-
Series
Nature Photography Makes Me A Better Lawyer
Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.
-
What Defense Teams Must Know About PFAS Testing Methods
Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.
-
Series
Law School's Missed Lessons: Practical Problem Solving
Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.
-
Intellectual Property Challenges In AI-Driven Drug Discovery
Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.
-
Reel Justice: 'The Mastermind' And Juror Decision-Making
The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.
-
Learning From 2025 FCA Trends Targeting PE In Healthcare
False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.
-
Software Patents May Face New Eligibility Scrutiny
November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.
-
Opinion
A Uniform Federal Rule Would Curb Gen AI Missteps In Court
To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.
-
Riding The Changing Winds For AI Innovations At The USPTO
As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.
-
Series
The Law Firm Merger Diaries: Integrating Practice Groups
Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.
-
Opinion
Supreme Court Term Limits Would Carry Hidden Risk
While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.